The company is currently running two parallel programs with its lead product CAL02
designed to fight severe bacterial and viral infections.
Restoring health in critically ill patients suffering
of severe bacterial pneumonia
The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.
CAL02 is a phase 2-stage drug that has successfully been tested in ICU patients with severe community-acquired pneumonia.
Decoy drug to fight enveloped viruses,
such as COVID-19
By acting as a decoy to which the viral envelope preferentially binds instead of entering host cells, CAL02 sucks away the virus, preventing it from attacking host cells and from multiplying.
CAL02 targets the fundamental first step of COVID-19 infection: viral entry into host cells. The drug is ready for clinical trial in COVID-19 patients.